In a bid to decrease the count of injections needed to comply with pediatric vaccination requirement, hexavalent vaccine has been developed for primary and booster vaccination of infants and toddlers. At this juncture, India’s Panacea Biotec is trying to introduce the national immunization program of the government. It has signed a couple of agreements with Serum Institute of India (SII) and its wholly-owned subsidiary to manufacture and sell a type of hexavalent vaccine.
What is a Hexavalent Vaccine ?
A combination of six antigens, the vaccine intends to protect against Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus influenza type B and Polio. SII is permitted to manufacture and sell fully liquid whole cell Pertussis and Salk-based Injectable Polio Vaccine based Hexavalent vaccine developed and commercialised by Panacea Biotec, under collaboration. It is the first fully liquid-based hexavalent vaccine in the world.
Why Hexavalent Vaccines ?
Hexavalent vaccine has proved to be highly immunogenic, according to the recent studies. Following a main sequence of three doses managed at 1-2-month intervals from 2 months of age, Seroconversion or seroprotective titres of antibodies were attained in most of the infants against all antigens.
As demonstrated by the anamnestic response to booster, hexavac also induced immunologic memory vaccination at 12-18 months of age. These responses were equivalent with those seen following concomitant administration of Pentavac and monovalent hepatitis B vaccine. Surprisingly, they were also within the ranges witnessed for other relevant licensed vaccines. After comparing the immunogenicity of hexavac managed at either 2, 3 and 4 months or 2, 4 and 6 months, clinical studies proved that it can be used by either vaccination schedule.
To get this vaccine introduced in the National Immunisation Programme of the government and developing countries within 2 years, both companies(Panacea Biotec and Serum Institute of India) will work together with important stakeholders.
Panacea Biotec is an Indian research based pharmaceutical and health management company involved in research, manufacturing, and marketing of pharmaceutical formulations, vaccines, and natural products. Panacea Biotec has five research centres across India that specialize in the fields of pharmaceuticals, biotechnology, natural products and biopharmaceutics. Apart from this, Panacea Biotec will also work with government of different countries, World Health Organisation (WHO), Bill and Melinda Gates Foundation (BMGF), Global Alliance for Vaccines & Immunisation (GAVI) and other United Nations agencies.
Latest posts by Sazal Sharma (see all)
- Understanding the Indian agricultural market and the questions that lurk on its existence - January 15, 2019
- IRB Infrastructure achieves Financial Closure for 3rd HAM project in a month’s span, following two successive closures last month - October 20, 2018
- Google partners with 91 Springboard to support Tech entrepreneurship - August 10, 2018